Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Adaptive Biotechnologies Q1 2026 Earnings Call - MRD Momentum Drives Raised Guidance and Margin Expansion
Adaptive Biotechnologies delivered a robust first quarter, with MRD revenue surging 53% year-over-year to $67.1 million, driven by broad-based clinical adoption and accelerating biopharma demand. The ...
- MRD revenue grew 53% year-over-year to $67.1 million, with clinical and biopharma contributions at 65% and 35% respectively.
- ClonoSEQ clinical volumes reached a record 632,600 tests in Q1, up 41% year-over-year and 9% sequentially.
- Blood-based MRD testing now accounts for 49% of total MRD volume, with myeloma blood-based contributions rising to 29%.
- +7 more takeaways
"Bumble Inc" Q1 2026 Earnings Call - Tech Reset and AI-Driven Connection Model Take Center Stage
Bumble Inc delivered a Q1 2026 earnings report that marks a definitive pivot from a marketing-led growth strategy to a product and technology-led transformation. The company successfully executed a "q...
- Revenue declined 14% to $212 million in Q1 2026, with Bumble App revenue falling to $173 million from $202 million year-over-year, primarily due to the ongoing "quality reset" of the member base and losses from divested businesses.
- Adjusted EBITDA jumped 30% to $83 million, achieving a 39% margin, as the company slashed performance marketing spend to under 50% of pre-reset levels while maintaining disciplined cost controls.
- The company is executing a fundamental shift from a marketing-led growth model to a product and technology-led strategy, aiming to restore long-term revenue growth through innovation rather than paid acquisition.
- +7 more takeaways
Carlsmed Q1 2026 Earnings Call - 58% Revenue Growth and CMS Reimbursement Tailwinds
Carlsmed delivered a strong first quarter in 2026, with revenue jumping 58% year-over-year to $16.1 million. The growth was fueled by aggressive surgeon adoption, which expanded the user base by over ...
- Revenue surged 58% year-over-year to $16.1 million, driven by a 60% expansion in the surgeon user base and increased procedure volumes.
- Gross margins expanded by 220 basis points to 77.1%, supported by a 30% reduction in production lead times to six business days.
- Peer-reviewed data published in the Global Spine Journal shows a 74% reduction in 2-year revision rates for aprevo lumbar procedures compared to stock implants.
- +7 more takeaways
Tigo Energy Q1 2026 Earnings Call - Revenue Surges 34%, Margin Expansion Signals Turnaround
Tigo Energy reported a sharp revenue rebound in Q1 2026, up 33.7% year-over-year to $25.2 million, driven by a strong European recovery and strategic product launches. Gross margins expanded to 42.8%,...
- Total revenue surged 33.7% year-over-year to $25.2 million in Q1 2026, marking a decisive rebound after a period of stagnation.
- Gross margins expanded to 42.8% from 38.1% in the prior year period, primarily due to the absence of warranty-related charges and disciplined cost control.
- EMEA accounted for 69.5% of revenue, with Italy growing 140.8% sequentially and Eastern European markets like Poland and the Czech Republic showing strong momentum as competitors withdrew.
- +7 more takeaways
Alight Solutions Q1 2026 Earnings Call - New CEO Exceeds Guidance Amidst Recurring Revenue Decline and Strategic Leadership Hires
Alight Solutions delivered a stronger-than-expected first quarter of 2026, with revenue of $534 million beating the high-single-digit decline guidance. The outperformance was driven by a 29% surge in ...
- Revenue of $534 million exceeded guidance, driven by a 29% year-over-year increase in project revenue to $36 million and earlier-than-expected partner revenue recognition.
- Recurring revenue declined 4% year-over-year to $498 million, partially offset by the project revenue surge, resulting in a consolidated 3% revenue decrease.
- Adjusted EBITDA of $104 million fell 12% year-over-year but beat expectations, supported by project revenue flow-through and lower-than-anticipated employee healthcare expenses.
- +9 more takeaways
Cumberland Pharmaceuticals Q1 2026 Earnings Call - Apotex Deal Unlocks $109M Cash, Pivots to Pipeline
Cumberland Pharmaceuticals is selling its entire commercial portfolio to Apotex for $109 million in cash, marking a decisive pivot from a branded drug marketer to a pure-play development-stage biotech...
- Cumberland Pharmaceuticals signed a transformative agreement to sell its entire portfolio of marketed products to Apotex for $100 million in cash, subject to shareholder approval.
- The transaction includes an additional $9 million for inventory, transitional support services, and a milestone payment tied to future product sales.
- Cumberland will no longer target double-digit revenue growth, as Apotex will assume all sales, marketing, medical, manufacturing, and FDA fee responsibilities post-close.
- +7 more takeaways
BigBear.ai Q1 2026 Earnings Call - Backlog Surges 14% as GenAI Shift Boosts Margins
BigBear.ai reported Q1 2026 revenue of $34.4 million, flat year-over-year, but the real story is the structural pivot underway. Gross margins expanded nearly 1,300 basis points to 34%, driven by a del...
- Revenue of $34.4 million remained flat year-over-year, but gross margins expanded nearly 1,300 basis points to 34%, reflecting a successful shift toward higher-margin generative AI platforms post-Ack Sage acquisition.
- Backlog surged 14% to $281.9 million, driven by a $53 million classified sole-source intelligence contract and new wins in shipbuilding simulation and airport travel screening.
- The company is restructuring its go-to-market approach by aligning dedicated sales, technology, and delivery teams directly around national security and trade operators to accelerate execution.
- +7 more takeaways
Entravision Communications Q1 2026 Earnings Call - ATS Drives 114% Revenue Surge as Media Segment Invests for Turnaround
Entravision Communications reported a 114% year-over-year revenue increase to $197 million in Q1 2026, driven almost entirely by explosive growth in its Advertising Technology and Services (ATS) segme...
- Consolidated revenue surged 114% to $197 million in Q1 2026, reversing a prior-year operating loss into a $20.7 million operating income.
- ATS segment revenue exploded 204% to $155 million, with operating profit jumping 427% to $34.3 million, highlighting the segment's scalability.
- Media segment revenue grew just 4% to $42.4 million, but posted a widened operating loss of $5.2 million versus $2.6 million loss in Q1 2025 due to higher cost of revenue and strategic investments.
- +7 more takeaways
Skyworks Solutions Q2 FY2026 Earnings Call - Android Design Win and Qorvo Merger Progress Drive Outlook
Skyworks Solutions delivered a strong Q2 FY2026, posting revenue of $944M and EPS of $1.15, both beating guidance. The results were fueled by healthy mobile sell-through and robust broad market growth...
- Skyworks Solutions reported Q2 FY2026 revenue of $944 million, exceeding the high end of its guidance range by approximately $20 million.
- Diluted earnings per share came in at $1.15, beating the high end of guidance by $0.05 and the midpoint by $0.11.
- The company secured a multi-generational design win with a leading Android OEM, expected to generate over $1 billion in revenue through 2030.
- +10 more takeaways
Trevi Therapeutics Q1 2026 Earnings Call - Securing 2030 Runway and Launching Pivotal IPF Trials
Trevi Therapeutics has secured its financial future through a strategic capital raise, extending its cash runway to 2030 while positioning itself to fund pivotal Phase III trials for its lead chronic ...
- Trevi ended Q1 2026 with $172 million in cash and marketable securities, excluding $162 million in net proceeds from an underwritten common stock offering completed in April 2026.
- The recent capital raise extends Trevi's cash runway through 2030, funding development through potential FDA approval for IPF-related chronic cough and pre-commercial activities.
- Phase III protocols for IPF-related chronic cough are finalized, with the first pivotal study expected to initiate this quarter and the second in the second half of 2026.
- +9 more takeaways